STOCKHOLM, Oct 9 (Reuters) - Danish drugmaker Novo
Nordisk said on Thursday it had agreed to buy United
States based Akero Therapeutics, a clinical-stage company
developing innovative treatments for patients with serious
metabolic diseases marked by a high unmet medical need.